检索结果-南通市图书馆

Carrying Railway 5G Service Application by Multi-technology Convergence

在线全文

学校读者我要写书评

暂无评论

Chinese Railways 2023年第1期 35-44页

作者： YANG Rui guo guifang ZHAO Wuyuan ZHENG Mingda Beijing Railway Communication Technology Center 不详

The application scenarios of railway radio communication are complex,while the existing narrowband communication such as GSM-R and radio train dispatching system fails to meet the requirements of service application *** carrying capacity of railway 5G-R has been greatly improved,mainly for wide-area train-ground communication services such as dispatching communication,train control and train operation safety ***,for large passenger stations,freight yards,maintenance bases and other places with densely populated railway operators,it is unable to carry overall railway service applications limited by the spectrum bandwidth of 5G private networks,so it is necessary to consider various radio technologies for *** paper also elaborates the railway service application scenarios,analyzes the characteristics of radio communication technologies such as 5G mmWave and the 6th-generation wireless LAN technology(Wi-Fi6),and discusses the schemes of multi-technology convergence carrying railway 5G service applications.

关键词： 5G-R service application technology convergence 5G mm Wave WLAN

Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2009年第9期8卷 526-530页

作者： Liangping Xia guifang guo Huijuan Oiu Bei Zhang Feifei Zhou VIP Region Cancer Center Sun Yat-sen University National Laboratory of Oncology in South China Guangzhou510060 China

Objective： The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer. Methods： All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate （CR ＋ PR ＋ SD） and response rate （CR ＋ PR） were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too. Results：（1） There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. （2） The disease control rate and response rate in the whole group was 73.5% （95% CI： 65.5%-81.5%） and 29.1% （95% CI： 20.9%-37.3%）, respectively; In first-line setting group they were 70.0% （95% CI： 55%-85%） and 41.7% （95% CI： 25.6%-57.8%）, respectively; In non-first line setting group they were 71.6% （95% CI： 61.8%-81.4%） and 23.5% （95% CI： 14.3%-32.7%）, respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant （P = 0.045）. （3） The incidence of acne-like rash was 72.0% （95% CI： 64.8%-79.2%）, the degree Ⅰ-Ⅱ and degree Ⅲ-Ⅳ account for 56.0% （95% CI： 48.1%-63.9%） and 16.0% （95% CI： 10.1%-21.9%）, respectively. No treatment related death, and the hypersensitivity was under control. Conclusion： This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer.

关键词： Chinese patient colorectal cancer cetuximab efficacy side effects

Non-platinum doublets versus single agents in non-small cell lung cancer （NSCLC） patients with elderly age and/or poor performance status： a meta-analysis

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2011年第3期10卷 134-139页

作者： Huijuan Qju Fang Wang guifang guo Feifei Zhou Wenzhuo He Liangping Xia State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen Universty Cancer Center Guangzhou 510060 China Tumor Center The Foshan First People＇s Hospital Foshan 510060 China

Objective： The aim of the study was to compare the efficacies and toxicities of non-platinum doublets （doublets group） with a non-platinum single agent （single-agent group） in previously untreated advanced non-small cell lung cancer （NSCLC） patients with elderly age and/or poor performance status （PS）. Methods： The PubMed database was screened. Subsequently, the hazard ratios （HRs） for overall survival （OS） and progression-free survival （PFS）, relative risks （RRs） for overall response rate （ORR） and one-year survival, and odds ratios （ORs） for the different types of toxicities were pooled using the Review Manager 5.0 package. Results： This study comprised of 1427 patients enrolled in four randomized controlled trials. The pooled HR showed that the doublet group could increase ORR （P = 0.002） with no heterogeneity （P = 0.64）, and might improve OS （P = 0.01 / P = 0.06） with heterogeneity （P 0.001）. There was no significant difference in PFS （P = 0.16） and one-year survival （P = 0.25） between two treatment groups. The doublet group led to more grade 3/4 neutropenia and thrombocytopenia than the single-agent group （P = 0.02 and P = 0.000, respectively）. The incidences of grade 3/4 anemia, vomiting, mucositis, constipation, diarrhea, neurotoxicity, allergy, and fatigue between the two treatment groups were insignificant. Conclusion： Except for neutropenia and thrombocytopenia, the non-platinum doublets could increase ORR, and might improve OS for NSCLC patients with elderly age and/or poor PS without addition of more side effects; however, the doublets showed an increased rate of neutropenia and thrombocytopenia. The addition of doublets may not improve PFS and one-year survival.

关键词： fielderly non-small cell lung cancer (NSCLC) meta-analysis doublets single non-platinum

Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting:the summary based on publications

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2010年第3期9卷 137-141页

作者： Liangping Xia Yuming Rong guifang guo Huijuan Qiu Feifei Zhou Fang Wang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen Universty Cancer Center Guangzhou 510060 China

Objective： The combination of cetuximab with standard chemotherapy was not widely studied though it was recommended by NCCN 2009 to apply in non-small cell lung cancer （NSCLC） first-line setting. The aim of this study was to summary the efficacy and safety profiles of all the NSCLC patients available in openly published papers treated with above mentioned regimens. Methods： The PubMed database was used to search all the papers on NSCLC associated with cetuximab treatment, and only the clinical trails applied cetuximab combined with doublets cytotoxic chemotherapy in first-line setting till to 30 November 2009 were collected. And the medians and their 95% CI of objective response rate （ORR）, progression free survival （PFS）, overall survival （OS）, and the common adverse events were calculated. Results：（1） Eight papers including 1032 patients were collected, and all cases were at advanced stage. （2） The ratio of male and female patients was 1.6, 50.1% patients were adenocarcinoma and 28.2% patients were squamous cell carcinoma （SCC）, 90.0% patients were PS = 0-1, and 78.2% patients were white ethnic. （3） The disease control rate （DCR）, ORR, PFS, and OS were 65.2% （95% CI： 60.7%-69.7%）, 33.2% （95% CI： 30.3%-36.1%）, 5.0 months （95% CI： 4.7-5.3） and 10.9 months （95% Cl： 9.6-12.2）, respectively. Conclusion： This is the first study to summarize the efficacy and safety profiles of cetuximab combined with chemotherapy in NSCLC first-line setting based on all available patients. The addition of cetuximab caused promising prognosis and acceptable side effects excepting higher incidence of neutropenia, and febrile neutropenia.

关键词： cetuximab non-small cell lung cancer (NSCLC) first-line setting chemotherapy efficacy adverse event

在线全文

学校读者我要写书评

暂无评论

两轮独立驱动电动车的转矩协调控制

西安交通大学学报 2009年第7期43卷 53-57页

作者：许鹏曹秉刚曹建波郭桂芳西安交通大学电动汽车研究开发中心西安710049 中国人民解放军71811部队河南信阳464000

为了对独立驱动电动车的2个驱动轮的转矩进行协调控制,研究了驱动系统的结构,建立了电动车运动模型.根据电动车的转动平衡,发现电动车在高速转弯时,外侧轮的受力明显高于内侧轮.由于道路状况的变化,当2个车轮分别在摩擦系数不同的路面... 详细信息

为了对独立驱动电动车的2个驱动轮的转矩进行协调控制,研究了驱动系统的结构,建立了电动车运动模型.根据电动车的转动平衡,发现电动车在高速转弯时,外侧轮的受力明显高于内侧轮.由于道路状况的变化,当2个车轮分别在摩擦系数不同的路面行驶时,车轮的受力也不同,因此采用神经网络PID控制方法,对2台轮毂式电动机分别进行了控制.通过系统仿真与实验研究,表明该模型及控制方法可以很好地反映电动车在各种工况下的响应特性,提高电动车的运行安全性与稳定性.

关键词：电动车神经网络独立驱动转矩协调控制

慢性肾脏病非肾脏替代治疗住院患者衰弱现状及其影响因素

在线全文

学校读者我要写书评

暂无评论

中国护理管理 2022年第6期22卷 868-873页

作者：杨臻郭桂芳北京大学护理学院北京市100191

目的:调查慢性肾脏病非肾脏替代治疗住院患者衰弱现状并分析其影响因素,为早期识别高危人群并进行衰弱管理提供依据。方法:采用方便抽样法,选取北京某三级甲等医院311名慢性肾脏病非肾脏替代治疗住院患者进行横断面调查,调查工具包括一... 详细信息

目的:调查慢性肾脏病非肾脏替代治疗住院患者衰弱现状并分析其影响因素,为早期识别高危人群并进行衰弱管理提供依据。方法:采用方便抽样法,选取北京某三级甲等医院311名慢性肾脏病非肾脏替代治疗住院患者进行横断面调查,调查工具包括一般资料调查表、中文版Tilburg衰弱评估量表(TFI)、年龄校正查尔森共病指数、全球领导人营养不良倡议标准、抑郁自评量表、领悟社会支持量表。结果:回收有效问卷311份,中文版TFI检出183人(58.8%)存在衰弱。Logistic回归分析结果显示,营养不良、重度共病、抑郁是慢性肾脏病非肾脏替代治疗住院患者衰弱的危险因素(P<0.05),而高水平的社会支持是其保护性因素(P<0.05)。结论:慢性肾脏病非肾脏替代治疗住院患者中衰弱的患病率较高,在临床工作中应引起重视,医务工作者应将营养干预、共病管理、心理干预、社会支持系统的构建作为衰弱预防与慢病管理的重要内容纳入临床实践。

关键词：慢性肾脏病衰弱非肾脏替代治疗中文版Tilburg衰弱评估量表

Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer:a report of 6 cases

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2010年第9期9卷 502-506页

作者： Fang Wang Liangping Xia guifang guo Huijuan Qiu Feifei Zhou Bei Zhang Li Zhang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou 510060 China

Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line *** study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line ***:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, *** short-term efficacies and safeties were ***:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole *** were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) *** were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).*** was no treatment-associated death and no cetuximab-associated *** incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with ***:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.

关键词： cetuximab non-small cell lung cancer (NSCLC) efficacy safety non-first line

The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2012年第10期11卷 585-591页

作者： Huijuan Qju Wenzhuo He Chenxi Yin guifang guo Fang Wang Feifei Zhou Chang Jiang Liangping Xia State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Tumor Center The First Affiliated Hospital of Sun Yat-sen University Guangzhou 510060 China Tumor Center The Foshan First People's Hospital Foshan 510060 China

Objective: Bevacizumab has been challenging in the treatment of metastatic breast cancer. To investigate its efficacy, optimal partner to combine with and maintenance therapy, we performed a retrospective study based on Chinese patients with metastatic breast cancer (MBC). Methods: Patients with MBC treated with bevacizumab-contained regimens at the Sun Yat-sen University Cancer Center from 2006 to 2010 were recruited to the study. The primary endpoints were overall survival (OS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR). These endpoints were analyzed using the Kaplan-Meier and Chi-squared tests, respectively. Results: (1) A total of 229 cycles of bevacizumab with a median cycle of 7 (1-34) were administered among 25 patients. (2) In the whole group, ORR and DCR were 60% (15/25) and 76% (19/25), respectively. The mTTP was 5 months (1-21), mOS from diagnosis was 48 months (13-172), mOS from bevacizumab administration was 24 months (1-45). (3) Both ORR (73.7% vs. 16.7%, P = 0.023) and DCR (94.7% vs. 33.3%, P = 0.005) were significant higher once patients treated with the combination of taxanes-based regimen and bevacizamab when compared with the combination with non-taxanes-based regimens. (4) In the taxanes-based group, no matter bevacizumab used in first line or non-first line, the differences of ORR (P = 0.637) and DCR (P = 0.316) were insignificant. However, the maintenance therapy with bevacizumab will bring more longer TTP (P < 0.001) than those without maintenance therapy. Conclusion: Taxanes-based regimens were the optimal candidate to combine with bevacizumab regardless the timing in palliative setting, however, the maintenance therapy with bevacizumab should be considered once indicated.

关键词： bevacizumab efficacy maintenance therapy metastatic breast cancer

Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2009年第11期8卷 669-674页

作者： Liangping Xia guifang guo Bei Zhang Ruihua Xu Huijuan Qiu Yuming Rong Feifei Zhou Fang Wang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medicine Sun Yat-sen Universty Cancer Center Guangzhou 510060 China

Objective： Cetuximab is an effective medicine for colorectal cancer bearing wild type Kras. However, few studies of cetuximab on patients with noncolorectal gastrointestinal cancer were available now. The aim of this study was to summarize the efficacy and safety profiles base-on the experiences of 16 patients with noncolorectal gastrointestinal cancer accepted cetuximab-contained regimens treatment. Methods： The clinical data of all patients with noncolorectal gastrointestinal cancer treated by cetuximab combined with chemotherapy and/or radiotherapy from October 1st 2006 to Jun 30th 2009 in Sun Yat-sen University Cancer Center were collected. Results：（1） A total of 16 patients enrolled, including gastric cancer, esophageal carcinoma, pancreatic cancer and cholangiocarcinoma （8, 6, 1 and 1, respectively）. The cetuximab was administered 92 cycles totally with median cycle of 4. （2） PR, SD and PD obtained in 4, 3 and 2 patients respectively in cetuximab ＋ chemotherapy group. The disease control rate, median l-rP and median OS were 77.8% （7/9）, 3.5 months and 3.5 months, respectively. （3） Both of patients in cetuximab ＋ radiotherapy group achieved PR with median TTP of 4 months and 7 months, with median OS of 14 and 28 months, respectively. （4） in evaluable patients, 3 PR obtained in first-line setting, 1 PD and 1 SD achieved in second-line setting, 2 SD and 1 PD appeared in third-line and more than third-line setting. （5） The commonly side effect was neutropenia, however, rash and hypomagnesemia were the common side effects related to cetuximab. Conclusion： Cetuximab-contained regimens show a promising disease control rate, especially in first-line setting, in patients with noncolorectal gastrointestinal cancer, and the side effects both related to cytotoxic agents and related to cetuximab itself is tolerable and manageable. Of course, more phase Ⅲ clinical trails are needed urgently.

关键词： cetuximab noncolorectal gastrointestinal cancer chemotherapy efficacy